BioCentury | Jun 20, 2020
Product Development

Regeneron’s commercial future

...diseases, with Regeneron having rights to a combination of pozelimab and Alnylam’s C5 inhibitor cemdisiran (ALN-CC5...
BioCentury | Apr 8, 2019
Company News

Regeneron aims for intracellular targets via Alnylam deal

...combination therapy including Regeneron's anti-complement 5 (C5) mAb pozelimab (REGN3918) and Alnylam's RNAi therapeutic cemdisiran (ALN-CC5...
...modality (see "Agreement to Differ" ). Regeneron lost $7.68 to $401.26 on Monday. Paul Bonanos, Assistant Editor ALN-CC5 REGN3918 Alnylam...
BioCentury | Nov 9, 2018
Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

...Nov. 7 that recruitment challenges prompted it to discontinue a Phase II trial of cemdisiran (ALN-CC5...
...NASDAQ:JAZZ), Dublin, Ireland Genomic Health Inc. (NASDAQ:GHDX), Redwood City, Calif. Business: Endocrine/Metabolic, Hematology, Cancer, Diagnostics Jennie Walters ALN-CC5 Erwinase...
BioCentury | Nov 7, 2018
Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

...revealed Wednesday that recruitment challenges prompted it to discontinue a Phase II trial of cemdisiran (ALN-CC5...
...a loss per share of $0.06 in last year’s quarter. Consensus figures provided by FactSet. BC Staff ALN-CC5 Erwinase...
BioCentury | Dec 16, 2016
Company News

Alnylam, Sanofi deal

...Alnylam said Sanofi’s Sanofi Genzyme unit declined to exercise an option to co-develop and co-commercialize ALN-CC5...
...Canada and Western Europe under a 2014 deal to develop and commercialize Alnylam's RNAi therapeutics. ALN-CC5...
...2014 ). Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Hematology Nora Weintraub ALN-CC5 Alnylam...
BioCentury | Oct 10, 2016
Finance

Program or platform?

...American Society of Hematology , multiple analysts expect to see additional Phase I/II data for ALN-CC5...
BioCentury | May 9, 2016
Clinical News

ALN-CC5: Phase I/II ongoing

...Alnylam said it will narrow its development program for ALN-CC5 to target poor responders to Soliris...
...responders to Soliris eculizumab and PNH patients who require Soliris sparing. The company was developing ALN-CC5...
...of a 3-part, U.K. Phase I/II trial evaluating single and multiple ascending doses of subcutaneous ALN-CC5...
BioCentury | May 4, 2016
Company News

Alnylam tumbles on ALN-CC5 update

...after reporting that it will narrow its development program for paroxysmal nocturnal hemoglobinuria (PNH) therapy ALN-CC5...
...to treat PNH in that population, and intends to begin trials early next year of ALN-CC5...
...complement 5 (C5). Alexion markets Soliris to treat PNH and HUS. Both treatments target C5; ALN-CC5...
BioCentury | Dec 14, 2015
Clinical News

ALN-CC5: Additional Phase I/II data

...ALN-CC5 reduced mean maximum serum C5 levels by up to 98%. Specifically, single doses of ALN-CC5...
...and 98% at the 900 mg dose vs. 13% for placebo (p<0.05 for all). Once-weekly ALN-CC5...
...evaluating ALN-CC5 in about 16 patients with PNH. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Product: ALN-CC5...
BioCentury | Dec 11, 2015
Company News

Alnylam provides pipeline update

...12, 2014) . The POC data include results from studies of fitusiran ( ALN-AT3 ), ALN-CC5...
...fitusiran to treat hemophilia A and B and from a Phase I/II dose-ranging study of ALN-CC5...
...nocturnal hemoglobinuria (PNH). Fitusiran is an RNAi therapeutic targeting anti-thrombin III (AT3; SERPINC1 ) mRNA. ALN-CC5...
Items per page:
1 - 10 of 18